PrOD与LDV/SOF方案较未治疗可改善HCV感染者生存
在ERCHIVES退伍军人HCV感染队列中,比较PrOD或LDV/SOF治疗者与倾向评分匹配的未治疗者的生存。治疗组死亡率更低(PrOD 0.3%、LDV/SOF 1.4%、未治疗2.5%,P<.001),治疗及获得SVR均与更低死亡风险独立相关。
要点
- PrOD或LDV/SOF治疗与未治疗相比死亡比例更低(0.3%、1.4% vs 2.5%)。
- 治疗与死亡风险降低独立相关(HR 0.43,95%CI .33-.57)。
- 获得SVR与更低死亡风险相关(HR 0.57,95%CI .33-.99)。
核心结论
- PrOD或LDV/SOF治疗及获得SVR均与显著死亡获益相关,且在治疗前18个月内即可显现。
研究设计与样本
- 基于ERCHIVES全国HCV感染退伍军人队列,纳入启动PrOD或LDV/SOF者,并排除HIV、HBsAg阳性、肝细胞癌或缺失HCV RNA或FIB-4者。
- 为每例治疗者以倾向评分匹配1例从未启动治疗的对照,共分析PrOD 1473例、LDV/SOF 5497例及匹配未治疗6970例。
主要发现
- 死亡比例:PrOD组0.3%、LDV/SOF组1.4%、未治疗对照组2.5%(P<.001)。
- 治疗组随访至18个月存活比例显著高于未治疗对照组(P<.001)。
- 多变量Cox回归:任一方案治疗与死亡风险降低相关(HR 0.43,95%CI .33-.57)。
- 获得SVR与死亡风险降低相关(HR 0.57,95%CI .33-.99)。
临床怎么用
- 对无HIV/HBsAg阳性/肝细胞癌且资料完整的HCV感染者,PrOD或LDV/SOF治疗可作为降低死亡风险的策略。
- 治疗决策中应重视获得SVR,因其与进一步死亡风险降低相关。
局限性
- 为观察性队列并采用倾向评分匹配,可能存在未测量混杂。
- 研究基于退伍军人队列,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interferon-based regimens are associated with a substantial survival benefit for persons infected with hepatitis C virus (HCV). Survival data with direct-acting antiviral agents are not available. We conducted this study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality. METHODS: In the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a well-established national cohort of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 scores. For each case, we identified a propensity score-matched control never initiated on treatment. Primary outcome was survival. Outcomes were assessed using frequency of events, Kaplan-Meier curves, and Cox proportional hazards regression analyses. RESULTS: We identified 1473 persons on PrOD, 5497 on LDV/SOF, and 6970 propensity score-matched untreated persons. Treated persons were more likely to be obese and have cirrhosis, but less likely to have stage 3-5 chronic kidney disease (CKD), alcohol or drug abuse or dependence diagnosis, and anemia. The proportion of persons who died was higher in the untreated group compared with either treatment group (PrOD, 0.3%; LDV/SOF, 1.4%; untreated controls, 2.5%; P < .001). A significantly larger percentage of treated patients survived to 18 months of follow-up, compared with untreated controls (P < .001). In multivariable Cox regression analysis, treatment with either regimen (hazard ratio [HR], 0.43; 95% confidence interval [CI], .33-.57) and attainment of sustained virologic response (SVR) were associated with significantly lower mortality (HR, 0.57; 95% CI, .33-.99). CONCLUSIONS: Treatment with PrOD or LDV/SOF and SVR are associated with a significant mortality benefit, apparent within the first 18 months of treatment.
引用
- Butt AA, Yan P, Simon TG, et al. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin Infect Dis. 2017. PMID: 28903508. doi:10.1093/cid/cix364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。